Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Stage III lung cancer is now treated by genotype as well as by stage: an EGFR mutation moves a patient from durvalumab consolidation to osimertinib consolidation. It is also the strongest hazard ratio in the lung cancer literature, which is a reason to read the overall survival data carefully when they arrive.
The current standard for unresectable stage III lung cancer, and the clearest evidence in the disease that consolidation immunotherapy converts responses into cures for some patients rather than merely delaying relapse.
Patients with stage III lung cancer that cannot be removed surgically should receive a year of durvalumab after completing chemoradiotherapy, provided they have not progressed. This roughly doubles the chance of being alive without progression at five years. Whether the benefit extends to PD-L1-negative tumours is contested, and the EGFR-mutated subgroup is better served by osimertinib (LAURA).
Query for this cancer: (TITLE:"Unresectable stage III non-small-cell lung cancer" OR ABSTRACT:"Unresectable stage III non-small-cell lung cancer" OR TITLE:"Locally advanced non-small-cell lung cancer" OR ABSTRACT:"Locally advanced non-small-cell lung cancer" OR TITLE:"Inoperable stage III NSCLC" OR ABSTRACT:"Inoperable stage III NSCLC" OR TITLE:"Stage IIIB and IIIC NSCLC" OR ABSTRACT:"Stage IIIB and IIIC NSCLC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Unresectable stage III non-small-cell lung cancer, not a curated reading list.